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Abstract: 
Introduction: Liver is a pivotal organ of the body and play very important role in the metabolism. If there is any 
problem in the liver then the herbs or different plants play an important role for the treatment of liver disorders. 
Objective of the study: The main objective of the study is to analyze the interferon aplha receptors and STAT1 as 
therapy predictors in hepatitis infection.  
Methodology of the study: This cross sectional study was conducted in hospital of Sialkot during September 2018 to 
January 2018. The purpose and benefits of the study were explained to each participant and informed written consent 
was obtained. By using non-probability convenience sampling, we enrolled treatment-naïve HCV mono-infected and 
HCV/HBV co-infected patients along with healthy controls. Out of the eligible patients, some were also positive with 
hepatitis B surface antigen (HbsAg) along with serum HBV-deoxyribonucleic acid (DNA) level.  
Results: The demographic values of patient group and control group shows a significant difference. The data suggest 
clearly that CD4 count decreases in abnormal liver function. There were non-significant relationship present in 
diseased group treated with different therapies like interferon and glutathione as as p<0.05. The level of 
micronutrients become decreases in diseased group. Of the eligible 171(88%) patients, 86(50.3%) were also positive 
with HbsAg. The final study sample had 191 subjects. Of them, there were 20(10.5%) in group-1a, 35(18.3%) in 
group-2a, 65(34%) in group-1b and 51(26.7%) in group-2b.  
Conclusion: It is concluded that hepatitis directly increase the liver enzymes even after receiving medication and 
other therapies. Expression rate of IFNAR-1 mRNA maybe useful index for predicting long-term efficacy of IFN 
therapy compared to STAT-1 and IFNAR-2. Replication of HBV-DNA is not the main factor leading to down-
regulation of IFN- receptors or STAT-1. 
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INTRODUCTION: 
Liver is a pivotal organ of the body and play very 
important role in the metabolism. If there is any 
problem in the liver then the herbs or different plants 
play an important role for the treatment of liver 
disorders. There are a number of plants which shows 
hepatoprotective property. Hepatitis B and C viruses 
can lead to hepatocellular carcinoma and cirrhosis-
related end-stage liver disease, which are potentially 
life-threatening liver diseases [1]. Hepatitis B and C 
need immediate worldwide attention as the infection 
rates are too high. More than 240 million people 
globally have chronic (long-term) liver infections. 
Every year, about 600,000 people die because of the 
acute or chronic consequences of hepatitis B, and more 
than 350,000 people die from hepatitis C-related liver 
diseases worldwide [2]. 
Hepatitis is a major public health problem and is 
endemic throughout the world especially in tropical 
and developing countries [3]. Hepatitis means 
inflammation of the liver. The liver is indispensable to 
our survival. It has synthetic, storage and 
detoxification functions. An abnormal LFT may 
signify a serious disease that can be identified only 
through further testing. These conditions include liver 
diseases, such as primary biliary cirrhosis (PBC), 
diseases of other organs such as Paget's disease of 
bone, and multi-organ diseases such as 
haemochromatosis [4]. However, the majority of 
people with an abnormal LFT in primary care settings 
will not have any such previously undetected disease 
[5]. They will have either no disease at all, or will be 
manifesting the effects of alcohol abuse or obesity. 
Due to shared mode of transmission, hepatitis C virus 
(HCV) /hepatitis B virus (HBV) co-infection 
represents significant public health issues worldwide. 
Owing to hepatotropic nature, HCV and HBV co-
infection is common in highly endemic areas and 
among subjects with increased possibility of parental 
infections. HCV causes persistent infection in 60-65% 
of HCV mono infected and 70-80% of HCV/HBV co-
infected patients. Signal transduction is mediated by 
rapid tyrosine phosphorylation of IFNAR-1 and JAK 
proteins, leading to activation of downstream STATs 
by phosphorylating critical serine and tyrosine 
residues [6]. STAT proteins are the key mediators of 
cytokine-induced gene expression and exert active 
role in anti-viral, anti-mycobacterial and anti-tumor 
responses against hepatitis. A recent review described 
multiple mechanisms related to JAK-STAT signaling 
pathway for modulation of HCV infection. Activated 
STAT-1 and STAT-2 bind IFN-regulatory factor 9 and 
form a heterotrimeric complex called IFN stimulated 
gene factor 3 (ISGF-3) [7]. Consequently, ISGF-3 
binds to IFN-stimulated response elements in the 
promoters of IFN-stimulated genes, thereby activating 
transcription. IFN expression and STAT may be 
directly involved in response to therapy and 
pathogenesis of viral hepatitis [8].  
Objective of the study 
The main objective of the study is to analyze the 
interferon aplha receptors and STAT1 as therapy 
predictors in hepatitis infection. 
 
METHODOLOGY OF THE STUDY 
This cross sectional study was conducted in hospital 
of Sialkot during September 2018 to January 2018. 
The purpose and benefits of the study were explained 
to each participant and informed written consent was 
obtained. By using non-probability convenience 
sampling, we enrolled treatment-naïve HCV mono-
infected and HCV/HBV co-infected patients along 
with healthy controls. Out of the eligible patients, 
some were also positive with hepatitis B surface 
antigen (HbsAg) along with serum HBV-
deoxyribonucleic acid (DNA) level. Detailed history 
was taken from all patients with special reference to 
duration of hepatitis, mode of infection, previous 
history of jaundice, HBV or HCV infection. A 
thorough clinical examination was carried out and 
stigmata of chronic liver disease, hepatosplenomegaly, 
ascites, etc. if present were noted.  
 
Blood investigation  
It includes Hemoglobin (Hb), total leucocytes count 
(TLC), differential leucocytes count (DLC), platelet 
count, level of micronutrients and LFT were done in 
all patients. The LFT included serum bilirubin, 
aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), serum alkaline phosphatase 
(SAP) and serum albumin. Abnormal values were 
defined as serum Bilirubin ≥1.5 mg/dl, 
ALT/AST≥50 IU/ml.  
 
Statistical analysis 
The data were sampled and entered into the SPSS 
worksheet for analysis. The alpha criterion was set at 
0.05 (95% confidence interval [CI]). After 
constructing a 2×2 contingency table, chi-square 
without Yates correction was used to find the 
association between the potential risk factors and 
hepatitis status. 
 
RESULTS: 
The demographic values of patient group and control 
group shows a significant difference. The data suggest 
clearly that CD4 count decreases in abnormal liver 
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function. There were non-significant relationship 
present in diseased group treated with different 
therapies like interferon and glutathione as as p<0.05. 
The level of micronutrients become decreases in 
diseased group. Of the eligible 171(88%) patients, 
86(50.3%) were also positive with HbsAg. The final 
study sample had 191 subjects. Of them, there were 
20(10.5%) in group-1a, 35(18.3%) in group-2a, 
65(34%) in group-1b and 51(26.7%) in group-2. The 
remaining 20(10.5%) were controls. Overall, 106 
(55.5%) were male and 85 (44.5%) were female. 
Comparison of demographic and clinical 
characteristics among the groups was done. 
 
Table 01: analysis of characteristics of patients and control. 
 
DISCUSSION: 
The chemokine IL-8 is an important member of the 
chemokine CXC family. The key function of IL-8 is to 
attract polymorphonuclear cells to sites of tissue injury 
and inflammation. IL-8 is synthesized by several cell 
types, including monocytes, macrophages, Kupffer 
cells, hepatocytes, and hepatic stellate cells [7]. IL-8 
levels are upregulated in the peripheral blood and 
liver, thereby indicating that increased tissue 
infiltration and macrophage-induced hepatic 
activation are mediated by the interaction between IL-
8 and CXCR-1 during hepatitis C infection [1]. 
Damage to the structural integrity of liver is reflected 
by an increase in the level of serum transaminase 
because these are cytoplasmic in location and are 
released into circulation after cellular damage [9]. It is 
generally accepted that the toxicity of carbon 
tetrachloride depends on the cleavage of the carbon-
chlorine bond to generate a trichloromethyl free 
radical, and this free radical reacts rapidly with oxygen 
to form a trichloro methyl peroxy radical, which may 
contribute to the hepatotoxicity and subsequent 
increase in hepatic enzymes [4]. 
Essential micronutrients are involved in many 
metabolic pathways in the liver, such as enzymatic 
functions and protein synthesis, oxidative damage and 
anti-oxidant defense, immunological competence, 
interferon therapy response regulations, and 
alterations of the virus genomes. Reactive oxygen 
species (ROS) have also been implicated in a number 
of hepatic pathologies in exacerbating liver diseases 
[10].  
HCV is a major cause of chronic liver disease. HCV 
infection frequently leads to chronic hepatitis with 
increasing risk of developing liver cirrhosis and HCC. 
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Interferon with or without ribavirin is the only drug 
with proven efficacy in treating chronic HCV 
infections. Unfortunately, these therapeutic models 
maintain the rate of sustained virologic response 
(SVR) to approximately 10-40%.  The effective 
advancement in the antiviral treatments against 
chronic hepatitis C is necessary [1]. 
CONCLUSION: 
It is concluded that hepatitis directly increase the liver 
enzymes even after receiving medication and other 
therapies. Expression rate of IFNAR-1 mRNA maybe 
useful index for predicting long-term efficacy of IFN 
therapy compared to STAT-1 and IFNAR-2. 
Replication of HBV-DNA is not the main factor 
leading to down-regulation of IFN- receptors or 
STAT-1. The distribution of micronutrients activities 
in blood may be an additional host-specific parameter 
with a predictive value for the responsiveness of 
patients to interferon therapy.  
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